Evidence map›Paper›PMID 37415866›Full record

ArticleRSC chemical biology2023

Designed ankyrin repeat proteins for detecting prostate-specific antigen expression

Melanie Gut, Birgit Dreier, Sven Furler, Jens Sobek, Andreas Plückthun, Jason P Holland

Open access · goldAbstract read
In one paragraph

Article in RSC chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Melanie GutUniversity of Zurich, Department of Chemistry Winterthurerstrasse 190 CH-8057, Zurich Switzerland jason.holland@chem.uzh.ch https://www.hollandlab.org https://twitter.com/HollandLab_ +41-44-63-53990.ORCID https://orcid.org/0000-0002-7844-0861
Birgit DreierUniversity of Zurich, Department of Biochemistry Winterthurerstrasse 190 8057 Zurich Switzerland.ORCID https://orcid.org/0000-0002-5124-9346
Sven FurlerUniversity of Zurich, Department of Biochemistry Winterthurerstrasse 190 8057 Zurich Switzerland.
Jens SobekFunctional Genomics Center Zurich, Eidgenössische Technische Hochschule (ETH) Zurich and University of Zurich Zurich Switzerland.ORCID https://orcid.org/0000-0001-5090-0603
Andreas PlückthunUniversity of Zurich, Department of Biochemistry Winterthurerstrasse 190 8057 Zurich Switzerland.ORCID https://orcid.org/0000-0003-4191-5306
Jason P HollandUniversity of Zurich, Department of Chemistry Winterthurerstrasse 190 CH-8057, Zurich Switzerland jason.holland@chem.uzh.ch https://www.hollandlab.org https://twitter.com/HollandLab_ +41-44-63-53990.ORCID https://orcid.org/0000-0002-0066-219X
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late-stage prostate cancer often acquires resistance to conventional chemotherapies and transforms into a hormone-refractory, drug-resistant, and non-curative disease. Developing non-invasive tools to detect the biochemical changes that correlate with drug efficacy and reveal the onset of drug resistance would have important ramifications in managing the treatment regimen for individual patients. Here, we report the selection of new Designed Ankyrin Repeat Proteins (DARPins) that show high affinity toward prostate-specific antigen (PSA), a biomarker used in clinical monitoring of prostate cancer. Ribosome display and

Identifiers

PMID37415866
PMCPMC10320840
OpenAlexW4377084865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.